Establishing Pediatric CNS Pharmacodynamic Measures as Tools to Enable Psychiatric Indications in Adolescents
This grant supports research to develop and improve brain-based tools and models for safely testing psychiatric medication dosing and effects in children and adolescents.
Funder: National Institutes of Health
Due Dates: February 13, 2026 (Forecasted)
Funding Amounts: Not yet specified; details will be available in the full NOFO.
Summary: Supports research to develop and refine pediatric CNS pharmacodynamic measures to enable psychiatric drug trials in adolescents.
Key Information: This is a forecasted opportunity; applications are not currently being accepted.
Description
The National Institute of Mental Health (NIMH) is forecasting a funding opportunity to support research focused on establishing and validating central nervous system (CNS) pharmacodynamic measures as tools to enable psychiatric medication trials in adolescents. The initiative aims to improve dosing strategies and safety in pediatric clinical trials by developing and refining CNS tools and models, such as EEG, fMRI, digital health measures, or cognitive assessments. Studies exploring the relationship between dosing, pharmacokinetics, and pharmacodynamics in children and adolescents with serious mental illnesses are encouraged. The overarching goal is to enhance the effectiveness and safety of pediatric psychiatric drug development by providing robust pharmacodynamic measures and associated models. Researchers in pediatric psychiatry, neuroimaging, clinical pharmacology, clinical trials, and related areas are encouraged to prepare for this upcoming Notice of Funding Opportunity (NOFO).
